Progestins and the endometrium in patients receiving tamoxifen by unknown
Sir
Since the anti-oestrogen tamoxifen has partial agonist, oestrogen-
like effects on the uterus, progestins could theoretically be used –
as in hormone replacement therapy (HRT) – to protect the uterus
from excessive stimulation. There are, however, very few data on
the effects of this association: therefore, we read with interest an
article by Powles et al (Br J Cancer 78: 272–275), who used
norethisterone in healthy, post-menopausal women receiving
tamoxifen in a chemoprevention trial. In this study, 3 months of
cyclic progestin therapy failed to reverse endometrial abnormali-
ties identified by transvaginal ultrasound (TVUS).
We observed a similar phenomenon in a series of patients with
early breast cancer. Fourteen post-menopausal patients with an
intact uterus, who had been on adjuvant tamoxifen (20 mg day21)
for a median of 10.5 months (range 1–43) received additional
progestin therapy as a treatment of hot flushes. Four patients had
megestrol acetate (40 mg day21 p.o.) for 6 consecutive weeks, and
ten received three fortnightly intramuscular injections of a depot
formulation of 500 mg medroxyprogesterone acetate. Before
starting treatment with the progestin, all patients underwent TVUS
which showed normal endometrium (, 4 mm thick) in eight
patients (57.1%) and endometrial thickening (median 12.5 mm,
range 6–20) in six (42.9%). Both megestrol acetate and medrox-
yprogesterone acetate were well-tolerated, and no patient reported
withdrawal bleeding. TVUS measurements were repeated in 12
patients after progestin therapy, showing a thickened endometrium
(median 16 mm, range 4–46) in 11 (91.6%). During a median
follow-up time of 24 months (range 9–27), endometrial samples
were obtained in seven patients (including the two patients who
did not repeat TVUS), showing benign tamoxifen-associated
abnormalities.
In another report, endometrial biopsies and TVUS measure-
ments were performed in 12 post-menopausal breast cancer
patients on tamoxifen who received additional progestins for a
median of 5 months (range 1–9) (Cohen et al, 1989). A decidual
reaction was observed in 11/12 patients (91.6%), while
endometrial thickness measured by TVUS remained abnormal
(median thickness 18 mm, range 6–40). Perhaps due to excessive
stromal decidualization and oedema after tamoxifen priming,
progestins have also been associated with the development of
benign megapolyps in breast cancer patients, leading to hysterec-
tomy (Berezowsky et al, 1994).
Taken together, these findings suggest that short-term addition
of progestins is not able to reverse or prevent tamoxifen-associated
uterine abnormalities detected by TVUS. As in HRT, effective
endometrial protection could probably be obtained with a regular,
prolonged co-administration of progestins and tamoxifen, starting
from the beginning of adjuvant hormone treatment. At present,
however, this is not recommended because detrimental effects on
disease-free and overall survival of patients cannot be excluded.
Thus, the only indication for the addition of progestins in this
setting remains the relief of hot flushes (Loprinzi et al, 1994),
which can be obtained with a very short (1–2 months) cycle of
treatment. Alternative strategies for endometrial protection, such
as progestagen-loaded intrauterine devices (Neven and Vergote,
1998), deserve to be investigated.
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